Handelsavisen
prelaunch
Companies Healthcare 7779.T
77
7779.T Tokyo Stock Exchange Advanced Medical Equipment & Technology

Cyberdyne Inc

¥265,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-13,9 %
ROE
-1,5 %
Net margin
-13,1 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Cyberdyne Inc develops and commercializes advanced medical equipment and technology, primarily focused on robotic exoskeletons and assistive devices for healthcare applications.

Business. Cyberdyne Inc is a Japanese company engaged in the Advanced Medical Equipment & Technology industry, primarily operating through a product-sale revenue model. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange under the ticker symbol 7779.T. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-1,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 7779.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 7779.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Cyberdyne Inc is a Japanese company engaged in the Advanced Medical Equipment & Technology industry, primarily operating through a product-sale revenue model. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange under the ticker symbol 7779.T. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Cyberdyne Inc's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage profile. The company holds significant liquidity with JPY 6.824 billion in cash and equivalents, which is 14.88% of total assets. However, negative operating and free cash flows of JPY -430 million and JPY -339 million, respectively, suggest ongoing cash burn despite strong asset base.

    Profitability metrics are negative, with a return on equity of -1.46% and a return on assets of -1.19%, both well below the industry median for advanced medical equipment firms. The company reported a net loss of JPY 576 million for the period, driven by an operating loss of JPY 609 million. These results indicate a need for operational restructuring or product innovation to restore profitability.

    Geographically, Cyberdyne Inc's revenue is concentrated in Japan, with no disclosed international segments in the latest financials. The company's business model is heavily dependent on domestic healthcare demand and regulatory approvals, which increases exposure to local economic and policy shifts.

    Growth trajectory is currently negative, with declining operating income and net income. The company's capital expenditures of JPY -305 million suggest ongoing investment in infrastructure, but this has not yet translated into improved profitability. Management will need to demonstrate a clear path to positive cash flow generation to attract long-term investors.

    Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses could become a concern if not addressed. There is no evidence of near-term dilution pressure, with basic and diluted shares outstanding aligned at 133.43 million.

    Recent filings and transcripts have not disclosed any material events that would significantly alter the company's risk profile. Investors should monitor the company's ability to reduce losses and improve cash flow generation in the coming quarters.

    Key takeaways
    • Cyberdyne Inc is operating at a net loss with negative cash flows, indicating a need for operational improvements.
    • The company maintains a strong liquidity position with JPY 6.824 billion in cash and equivalents.
    • Low debt-to-equity ratio of 0.01 suggests a conservative capital structure.
    • Negative return on equity and return on assets highlight poor profitability.
    • Revenue concentration in Japan increases exposure to local market risks.
    • No immediate liquidity or dilution risks are currently flagged.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥265,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥39.58B
    Net cash
    ¥6.39B
    Current ratio
    15.4
    Debt / equity
    0.0
    ROA
    -1.2%
    ROE
    -1.5%
    Cash conversion
    75.0%
    CapEx / revenue
    -7.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target¥305,00 · Median ¥305,00
    Low ¥200,00High ¥410,00
    EPS surprise
    −2 147,6 %
    reported vs consensus · miss
    Revenue surprise
    +6,2 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥200,00
    Mean¥305,00
    Median¥305,00
    High¥410,00
    Spot¥265,00
    +15.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-13,9 %Above median
    Net Margin-13,1 %Above median
    ROE-1,5 %Above median
    Capex / Rev-7,0 %Below median
    D/E0,01Above median
    Cash Conv0,75Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Cyberdyne Inc Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    7779.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage